Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe
Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe
复制标题
DOI：
10.2807/1560-7917.es2015.20.2.21008
复制
发表时间：
2015-01-15
期刊：
影响因子：
19
通讯作者：
Kahlmeter, G.
中科院分区：
文献类型：
--
作者：
Brown, D.;Canton, R.;Kahlmeter, G.
欧洲抗菌药物敏感性试验委员会（EUCAST）的成立是为了协调临床抗菌药物折点，并定义欧洲新药物的折点。分析了2009年至2012年欧洲抗菌素耐药性监测网络（EARS-Net）外部质量评估（EQA）活动的数据、2009年11月至2013年3月英国外部质量评估计划（UK NEQAS）的数据以及EUCAST在2013年第一季度通过问卷调查收集的数据，以调查EUCAST指南在欧洲的实施情况。随着时间的推移，观察到使用EUCAST断点的快速变化。在研究期结束时，EUCAST断点的实施数字来自EARS-Net数据的61.2%和来自英国NEQAS数据的73.2%。对EUCAST调查问卷的答复表明，18个国家超过50%的实验室使用EUCAST折点，8个国家10%至50%的实验室使用EUCAST折点，7个国家不到10%的实验室使用EUCAST折点。EUCAST纸片扩散法在12个国家的50%以上的实验室使用，在10个国家的10%至50%的实验室使用，在11个国家的不到10%的实验室使用。EUCAST指南的实施对于确保抗菌药物敏感性结果和抗菌药物耐药性监测的一致性临床报告至关重要。
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) was established to harmonise clinical antimicrobial breakpoints and to define breakpoints for new agents in Europe. Data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) external quality assessment (EQA) exercises from 2009 to 2012, from the United Kingdom External Quality Assessment Scheme (UK NEQAS) from November 2009 to March 2013 and data collected by EUCAST through a questionnaire in the first quarter of 2013 were analysed to investigate implementation of EUCAST guidelines in Europe. A rapid change to use of EUCAST breakpoints was observed over time. Figures for implementation of EUCAST breakpoints at the end of the studied period were 61.2% from EARS-Net data and 73.2% from UK NEQAS data. Responses to the EUCAST questionnaire indicated that EUCAST breakpoints were used by over 50% of laboratories in 18 countries, by 10 to 50% of laboratories in eight countries and by less than 10% in seven countries. The EUCAST disk diffusion method was used by more than 50% of laboratories in 12 countries, by 10 to 50% of laboratories in ten countries and by less than 10% in eleven countries. EUCAST guidelines implementation is essential to ensure consistent clinical reporting of antimicrobial susceptibility results and antimicrobial resistance surveillance.